SARTORIUS AG UNSP.ADR 1/5 (SRT4) - Net Assets
Based on the latest financial reports, SARTORIUS AG UNSP.ADR 1/5 (SRT4) has net assets worth €3.89 Billion EUR (≈ $4.55 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€9.87 Billion ≈ $11.54 Billion USD) and total liabilities (€5.98 Billion ≈ $6.99 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore SARTORIUS AG UNSP.ADR 1/5 cash flow conversion to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €3.89 Billion |
| % of Total Assets | 39.41% |
| Annual Growth Rate | 22.45% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 23.76 |
SARTORIUS AG UNSP.ADR 1/5 - Net Assets Trend (2021–2025)
This chart illustrates how SARTORIUS AG UNSP.ADR 1/5's net assets have evolved over time, based on quarterly financial data. Also explore SARTORIUS AG UNSP.ADR 1/5 balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for SARTORIUS AG UNSP.ADR 1/5 (2021–2025)
The table below shows the annual net assets of SARTORIUS AG UNSP.ADR 1/5 from 2021 to 2025. For live valuation and market cap data, see market cap of SARTORIUS AG UNSP.ADR 1/5.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €3.87 Billion ≈ $4.52 Billion |
-0.78% |
| 2024-12-31 | €3.90 Billion ≈ $4.56 Billion |
+41.33% |
| 2023-12-31 | €2.76 Billion ≈ $3.22 Billion |
+3.73% |
| 2022-12-31 | €2.66 Billion ≈ $3.11 Billion |
+54.57% |
| 2021-12-31 | €1.72 Billion ≈ $2.01 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to SARTORIUS AG UNSP.ADR 1/5's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €2.71 Billion | 100.00% |
| Total Equity | €2.71 Billion | 100.00% |
SARTORIUS AG UNSP.ADR 1/5 Competitors by Market Cap
The table below lists competitors of SARTORIUS AG UNSP.ADR 1/5 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Telekom Malaysia Bhd
KLSE:4863
|
$7.13 Billion |
|
AAK AB
ST:AAK
|
$7.13 Billion |
|
PSP SWISS ADR 1/5/SF1050
F:P7S0
|
$7.13 Billion |
|
Shandong Sinocera Func Material
SHE:300285
|
$7.14 Billion |
|
Konfoong Materials International Co Ltd
SHE:300666
|
$7.12 Billion |
|
Kingfa Sci&Tech Co Ltd
SHG:600143
|
$7.12 Billion |
|
Xp Inc
NASDAQ:XP
|
$7.12 Billion |
|
Shenyang Fortune Precision Equipment Co. Ltd. A
SHG:688409
|
$7.12 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SARTORIUS AG UNSP.ADR 1/5's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,764,800,000 to 2,706,800,000, a change of -58,000,000 (-2.1%).
- Net income of 154,900,000 contributed positively to equity growth.
- Dividend payments of 50,800,000 reduced retained earnings.
- Other factors decreased equity by 162,100,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €154.90 Million | +5.72% |
| Dividends Paid | €50.80 Million | -1.88% |
| Other Changes | €-162.10 Million | -5.99% |
| Total Change | €- | -2.10% |
Book Value vs Market Value Analysis
This analysis compares SARTORIUS AG UNSP.ADR 1/5's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.91x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.93x to 0.91x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €18.42 | €35.60 | x |
| 2022-12-31 | €29.08 | €35.60 | x |
| 2023-12-31 | €30.22 | €35.60 | x |
| 2024-12-31 | €40.05 | €35.60 | x |
| 2025-12-31 | €39.20 | €35.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SARTORIUS AG UNSP.ADR 1/5 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.72%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.38%
- • Asset Turnover: 0.36x
- • Equity Multiplier: 3.59x
- Recent ROE (5.72%) is below the historical average (15.62%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 25.30% | 9.25% | 0.61x | 4.52x | €192.87 Million |
| 2022 | 34.08% | 16.24% | 0.60x | 3.51x | €479.12 Million |
| 2023 | 9.94% | 6.05% | 0.35x | 4.71x | €-1.18 Million |
| 2024 | 3.04% | 2.48% | 0.33x | 3.65x | €-192.48 Million |
| 2025 | 5.72% | 4.38% | 0.36x | 3.59x | €-115.78 Million |
Industry Comparison
This section compares SARTORIUS AG UNSP.ADR 1/5's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $6,199,585,877
- Average return on equity (ROE) among peers: -8.85%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SARTORIUS AG UNSP.ADR 1/5 (SRT4) | €3.89 Billion | 25.30% | 1.54x | $7.12 Billion |
| SCHOTT Pharma AG & Co. KGaA (1SXP) | $419.42 Million | 24.02% | 0.76x | $2.39 Billion |
| RENAU.UNSP.ARD 1/5 EO-20 (56S0) | $2.67 Billion | 11.61% | 1.89x | $15.47 Billion |
| MEDIMI AB AK (79T) | $13.75 Million | -103.63% | 0.50x | $365.27K |
| TEVANO SYSTEMS HLDGS INC. (7RBA) | $-938.43K | 0.00% | 0.00x | $210.67K |
| STEVANATO GROUP SPA O.N. (87N) | $841.66 Million | 15.96% | 0.69x | $894.98 Million |
| Carl Zeiss Meditec AG (AFX) | $2.06 Billion | 8.69% | 0.65x | $2.23 Billion |
| CARL ZEISS MEDITEC ADR 1 (AFXA) | $2.17 Billion | 13.36% | 0.40x | $2.14 Billion |
| Bio-gate AG (BIG1) | $1.79 Million | -90.74% | 1.21x | $7.08 Million |
| COLOPLAST SP.ADR 1/10 DK1 (CBH) | $17.94 Billion | 28.16% | 1.68x | $12.73 Billion |
| ESSILORLUXOTTICA 1/2/O.N. (ESLC) | $35.88 Billion | 4.04% | 0.66x | $78.07 Billion |
About SARTORIUS AG UNSP.ADR 1/5
Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors; software apps for bioreactors and cell culture shake flasks; fermenters; cell culture media, biolayer interferometry, microbiological testing, and fluid management pro… Read more